The Patent Finder

Terms ending in 2042

Genmab A/S

Every in-force patent on Genmab A/S's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,247,065Method for Producing a Controlled Mixture of Two or More Different Antibodies
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,453,781Methods of Treating Cancer with a Combination of an Anti-VEGF Antibody and an Anti-Tissue Factor Antibody-Drug Conjugate
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,246,025Methods of Treating Cancer with a Combination of a Platinum-Based Agent and an Anti-Tissue Factor Antibody-Drug Conjugate
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 11,814,437Antibodies Binding to CD30 and CD3
In force
 · High confidence
Genmab A/SIn forceHigh confidence
US 12,747,294Anti-Sortilin Antibodies and Use Thereof
In force
 · High confidence
H. Lundbeck A/SIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Genmab A/S.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited